Publications by authors named "Natalia B Mikhailova"
Article Synopsis
- This analysis reviewed trends in 5185 hematopoietic cell transplantations (HCT) between 1990 and 2022, including 3237 allogeneic (alloHCT) and 1948 autologous (autoHCT) transplants.
- There was a significant improvement in event-free survival (EFS) for both autoHCT and alloHCT over time, attributed to a decrease in relapse rates and non-relapse mortality, respectively.
- Specific survival improvements were noted for various conditions, with autoHCT showing better outcomes in Hodgkin's disease and multiple myeloma, while alloHCT advancements were observed mainly in leukemia and lymphomas.
Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma.
Int J Clin Oncol
March 2022
Objectives: Therapy of patients with relapsed and refractory classic Hodgkin lymphoma (r/r cHL) after PD-1 inhibitors failure remains an unresolved issue. The aim of this study was to evaluate the efficacy and safety of the combination of nivolumab with brentuximab vedotin (Nivo + BV) after nivolumab monotherapy failure.
Methods: This study retrospectively analyzed 21 patients with r/r cHL who were treated with the combination of Nivo + BV after Nivo failure.
Immune checkpoint inhibitors (ICI) have demonstrated high therapeutic efficacy in relapsed or refractory classical Hodgkin lymphoma (r/r cHL). Nevertheless, despite the accumulated data, the question of the ICI therapy duration and efficacy of nivolumab retreatment remains unresolved. In this retrospective study, in a cohort of 23 adult patients with r/r cHL who discontinued nivolumab in complete response (CR), the possibility of durable remission achievement (2-year PFS was 55.
View Article and Find Full Text PDFThe introduction of nivolumab has changed the landscape of relapsed/refractory classical Hodgkin lymphoma (r/r cHL) treatment. Despite its clinical importance, this therapy may remain inaccessible for a significant number of patients worldwide, especially in low-income countries, due to its high cost. The results of pharmacokinetic analysis and clinical observations suggest the potential efficacy of low dose nivolumab in r/r cHL patients.
View Article and Find Full Text PDFThis single-center prospective clinical trial evaluated the combination of nivolumab plus bendamustine (NB) as a salvage regimen in classical Hodgkin lymphoma patients after failure of nivolumab monotherapy. A total of 30 patients received nivolumab (3 mg/kg) on D1,14 and bendamustine (90 mg/m) on D1, 2 of a 28-day cycle for up to 3 cycles. The ORR was 87% with 57% CR, 30% PR.
View Article and Find Full Text PDF